نتایج جستجو برای: bone marker

تعداد نتایج: 428975  

Journal: :iranian red crescent medical journal 0
hossein teimori cellular and molecular research center, school of medicine, shahrekord university of medical sciences, shahrekord, ir iran; cellular and molecular research center, school of medicine, shahrekord university of medical sciences, shahrekord, ir iran. tel: +98-3813346692, fax: +98-3813330709 saeede ashoori cellular and molecular research center, school of medicine, shahrekord university of medical sciences, shahrekord, ir iran mohamad taghi akbari department of medical genetics, faculty of medical sciences, tarbiat modares university, tehran, ir iran marjan mojtabavi naeini cellular and molecular research center, school of medicine, shahrekord university of medical sciences, shahrekord, ir iran morteza hashemzade chaleshtori cellular and molecular research center, school of medicine, shahrekord university of medical sciences, shahrekord, ir iran

conclusions it was demonstrated that the presence of del6q21 in b-cll patients indicates poor prognosis and on the contrary, presence of del17p13 points at the good prognostic value of the disease. results deletion of 17p13 was found in 11 (16.6%) and deletion 6q21 was present in 5 (7.5%). statistical analyses were performed to investigate the correlation of these molecular-cytogenetic findings...

Journal: :iranian journal of veterinary medicine 2013
mahdieh rezaei shahram jamshidi anna saffarpour mahdi ashouri davood sharifi

background: stem cell therapy in small animal medicineis still in its infancy and few in vitro and in vivo research projectsregarding animal mesenchymal stem cells (mscs) have beencarried out. on the other hand, cell tracking is the first step of thecell-based therapies and is essential to recognize cell fate posttransplantation. objectives: the aim of this study was toisolate, characterize, an...

Journal: :Clinical chemistry 1995
L M Demers L Costa V M Chinchilli L Gaydos E Curley A Lipton

Several biochemical markers of bone formation and bone resorption have recently been developed. These markers have been evaluated for clinical utility in patients with metabolic bone disease, including Paget disease and osteoporosis, and for their potential use in cancer patients whose disease has metastasized to bone. We have evaluated seven markers of bone turnover in the plasma and urine of ...

Journal: :BMC Biotechnology 2007
Kathrin I Odörfer Nina J Unger Karin Weber Eric P Sandgren Reinhold G Erben

BACKGROUND Immune-mediated rejection of labeled cells is a general problem in transplantation studies using cells labeled with any immunogenic marker, and also in gene therapy protocols. The aim of this study was to establish a syngeneic model for long-term histological cell tracking in the absence of immune-mediated rejection of labeled cells in immunocompetent animals. We used inbred transgen...

Journal: :Blood 2007
Caridad Martinez Ted J Hofmann Roberta Marino Massimo Dominici Edwin M Horwitz

Mesenchymal stromal cells (MSCs) have enormous potential for the regeneration of bone, cartilage, and other tissues derived from primitive mesoderm. Despite extensive research, there is still no single marker that reliably identifies MSCs within the bone marrow. Using immunocytochemistry and flow cytometry, we demonstrate here that the neural ganglioside GD2 is expressed by MSCs either newly is...

Journal: :Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1996
C Jarava J R Armas M Salgueira A Palma

Serum total alkaline phosphatase is the most commonly used biochemical marker of bone disease in renal patients, but alkaline phosphatase originates from different organs and sometimes lacks specificity. Bone isoenzyme measurement is considered superior to total alkaline phosphatase for the assessment of bone metabolism. We have studied the value of bone isoenzyme, determined by a new. IRMA (Ta...

Journal: :Journal of the National Cancer Institute 2013
Michael Gnant Jose Baselga Hope S Rugo Shinzaburo Noguchi Howard A Burris Martine Piccart Gabriel N Hortobagyi Janice Eakle Hirofumi Mukai Hiroji Iwata Matthias Geberth Lowell L Hart Peyman Hadji Mona El-Hashimy Shantha Rao Tetiana Taran Tarek Sahmoud David Lebwohl Mario Campone Kathleen I Pritchard

BACKGROUND Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor-positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. Moreover, in preclinical studies, mammalian target of rapamycin inhibition was associated with decreas...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید